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Abstract
Objectives: The aim was to assess the extent of coronary artery disease and revascularization
using baseline SYNTAX Score (bSS) and residual SYNTAX Score (rSS) in patients with cardio-
genic shock (CS) secondary to ST-segment elevation myocardial infarction (STEMI). The prog-
nostic impact of SYNTAX Score (SS) was evaluated and assessed for additive value over clinical
risk scores.
Background: bSS and rSS have been proven to be useful in risk stratification in stable coronary
artery disease as well as in acute coronary syndromes, but they have not been studied in STEMI
related CS.
Methods: Patients from a multinational prospective study of CS were analyzed. The study popu-
lation was divided into tertiles according to bSS. The Cox regression and receiver operating
characteristic (ROC) curves were used to assess the predictive power of SS.
Results: Of the 61 studied patients, 85% were male and the mean age was 67 years. Median
bSS was 22 (15–32) and rSS 7 (0–13). Ninety-day mortality was 43%. bSS had negative prog-
nostic value in multivariable analysis (HR 1.06, 95% CI 1.01–1.10). However, additive value
over clinical risk scores was limited. rSS was not associated with mortality, whereas post-
percutaneous coronary intervention (PCI) TIMI flow 3 of infarct-related artery (IRA) predicted
better survival.
Conclusions: In STEMI related CS, the added value of bSS and rSS over clinical assessment and
risk scores is limited. Our results suggest that while immediate PCI in order to restore blood flow
to the IRA is essential, deferring the treatment of residual lesions does not seem to be associ-
ated with worse prognosis.
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1 | INTRODUCTION
SYNTAX Score (SS) is an angiographic scoring system that measures
the burden of coronary artery disease and has been shown to be an
independent predictor of cardiovascular events and mortality in stable
coronary artery disease1 as well as in acute coronary syndromes
(ACS).2–6 In the current literature, there are no data describing the
prognostic value of baseline SS (bSS) in ST-segment elevation
myocardial infarction (STEMI) related cardiogenic shock (CS). Residual
SS (rSS) measures the extent of coronary disease after percutaneous
coronary intervention (PCI) and can be used as an indicator of com-
pleteness of revascularization. Current guidelines suggest multivessel
PCI in CS,7 but new data about revascularization strategies in CS have
been published after these recommendations: the CULPRIT-SHOCK
trial showed worse outcome in CS with multivessel PCI in comparison
with revascularization of culprit artery only.8 Previously, the predictive
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value of rSS has been shown in stable coronary artery disease,9–11 as
well as in patients with ACS,12–14 but not studied in the con-
text of CS.
The aim of this study was to evaluate the extent of coronary
artery disease and success of revascularization in STEMI-related CS
patients treated with PCI. Second, the predictive value of bSS and rSS
in CS patients was evaluated over clinical and angiographic values,
including TIMI flow grade of the infarct-related artery (IRA). Finally,
we assessed the additive prognostic value of SS over three clinical risk
scores: CardShock risk score,15 IABP-SHOCK II risk score16 and
GRACE risk score.17
2 | MATERIALS AND METHODS
2.1 | Study population
This is a sub-analysis of the CardShock study, a prospective observa-
tional multicenter investigation of the prognosis and treatment of
CS. The CardShock study was conducted from October 2010 to
December 2012 in eight European countries in nine hospitals.
The design, methodology and primary results have been published
before.15 The study was approved by local ethics committees and
conducted in accordance with the Declaration of Helsinki. Written
informed consent was obtained from each patient or a next of kin.
Briefly, adult patients who fulfilled predefined criteria for CS were
included within 6 hr from the detection of CS. The criteria for shock
were systolic blood pressure less than 90 mmHg for at least
30 minutes despite adequate fluid therapy or need for vasoactive
therapy, and ≥1 signs of inadequate organ perfusion: confusion or
altered mental status, cool extremities, oliguria less than 0.5 ml/kg/h
for the previous 6 hr, or blood lactate greater than 2 mmol/l. Patients
with ongoing hemodynamically significant arrhythmia, or shock after
cardiac or non-cardiac surgery were excluded.
Patients’ demographics, medical history and clinical characteristics
were collected. Hemodynamic parameters and laboratory measure-
ments were registered. Arterial blood lactate and pH were analyzed
locally and creatinine, high-sensitivity troponin T (hs-TnT), and N-
terminal pro-B-type natriuretic peptide (NT-proBNP) (Roche Diagnos-
tics, Basel, Switzerland) were analyzed centrally. Estimated glomerular
filtration rate (eGFR) was calculated from creatinine values using the
CKD-EPI Creatinine equation. Echocardiography was performed at
study entry. The patients were treated according to local practice and
given treatments were registered.
For the present substudy, angiographic images from the two larg-
est centers (Helsinki and Barcelona) were analyzed and combined with
the clinical data from the CardShock database. STEMI patients treated
with primary PCI or rescue PCI were included. STEMI was defined
according to the third universal definition of myocardial infarction.18
Exclusion criteria were previous coronary artery bypass grafting
(CABG), emergency CABG after angiography, or mechanical complica-
tion of STEMI as an etiology of CS. The primary endpoint was all-
cause mortality at 90-day follow-up. The vital status was confirmed
by the patient or the next of kin, or through hospital or population
registers.
2.2 | SYNTAX scores
SS was measured from angiographic images using the SS algo-
rithm.19 Two experienced cardiologists (MV and JS) analyzed the
angiograms post hoc blinded to patient data. The interobserver vari-
ability (tertial partitioning) for the SS examiners was calculated in
48 independently analyzed angiograms: Cohen’s Kappa statistics
was 0.59 (95% CI 0.40–0.78, P < 0.01) for bSS and 0.65 (95% CI
0.32–0.97, P < 0.001) for rSS, signifying moderate interobserver
reliability comparable to the SYNTAX trial1 and also to the previous
studies with ACS patients.3,5,21
All lesions with stenosis greater than 50% in vessels with diame-
ter of more than 1.5 mm were scored. SS was calculated at three time
points:
1. Baseline SS1 (bSS1) was measured from initial diagnostic angio-
gram. Completely occluded IRA with TIMI flow 0 or 1 was scored
as a total occlusion.
2. Baseline SS2 (bSS2) was measured after wiring or thrombectomy,
if TIMI flow of IRA improved and severity of the lesions could be
measured downstream. If TIMI flow did not improve or anatomy
of IRA could not be assessed, bSS2 was the same as bSS1.
3. Residual SS was measured after primary PCI was completed. If
further angiograms were performed during the hospital stay, the
rSS was measured after all PCI procedures.
2.3 | Statistical analysis
The continuous data are presented as means and standard deviations
(SD) or as medians and interquartile ranges (IQR). The study popula-
tion was divided into tertiles by bSS1. Differences between tertiles
were analyzed with one-way ANOVA, the Kruskal–Wallis or logistic
regression as appropriate. The changes in SS were compared with
Wilcoxon’s Signed-Rank test. The Kaplan–Meier method was used to
generate survival curves and log-rank test was used to assess differ-
ences in survival. The prognostic evaluation was also conducted in dif-
ferent rSS cutoffs (0, 8, and 12 points), defined in previous
literature.12,20,21 Receiver operating characteristic (ROC) curves were
constructed to assess the predictive power of bSS and rSS for 90-day
mortality. The association with mortality was assessed for relevant
control variables (age, gender, hypertension, diabetes, coronary artery
disease, previous myocardial infarction, previous PCI, chronic heart
failure, resuscitation, systolic blood pressure, left ventricular ejection
fraction (LVEF), eGFR, hs-TnT, NT-proBNP, arterial blood lactate, pH,
one-vessel disease, three-vessel disease, left main disease, chronic
total occlusion (CTO), acute thrombus, multivessel PCI, drug-eluting
stent, prior PCI TIMI flow 0, and post-PCI TIMI flow 3) by the univari-
ate Cox regression and variables with P-value less than 0.05 were
selected for multivariable analysis. The final multivariable model
included age, LVEF, arterial blood lactate, eGFR, NT-proBNP, and
post-PCI TIMI flow 3 and the model was built in a forward stepwise
method with the Cox proportional analysis. In addition, three multivar-
iable models were created to evaluate the additive prognostic value of
bSS and rSS over clinical risk scores: bSS or rSS and either CardShock
risk score,15 IABP-SHOCK II risk score16 or GRACE risk score.17 An
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interaction analysis between CS timing (before or after revasculariza-
tion) and rSS was also conducted. A two-tailed P-value of less than
0.05 was considered statistically significant. Statistical analyses were
performed using SPSS 24.0.0.0 statistical software (IBM Corp,
Armonk, NY, USA).
3 | RESULTS
3.1 | Baseline characteristics and SS results
The patient selection process (n = 61) for this substudy is described in
Figure 1. Briefly, mean age was 67 (12) years, 85% were male.
Median bSS1 at baseline was 22 (15–32). After wiring or thrombect-
omy, median bSS2 was 19 (11–30), significantly lower than bSS1
(P < 0.01). After revascularization, median rSS was 7 (0–13), lower
than bSS1 and bSS2 (both P < 0.01). Only two patients had second
angiography after primary PCI, but the angiogram for second proce-
dure was available for assessment for one patient only.
Table 1 summarizes baseline characteristics according to bSS ter-
tiles (the first tertile: bSS1 ≤ 18; the second tertile: bSS1 19–27; the
third tertile: bSS1 > 27). There were no differences among the tertiles
except for history of previous PCI that was lower in the first tertile in
comparison to higher tertiles (both P < 0.01). There were no differ-
ences in hemodynamic parameters and routine laboratory measure-
ments (Table 1).
3.2 | Angiographic findings
One-third of the patients had one-vessel disease, 39% had two-vessel
disease, and 23% three-vessel disease. In the first and the second bSS
tertiles, only one patient (5%) in each group had CTO, while in the
third tertile 75% had CTO (both P < 0.01). Over half of the patients
(64%) had acute occlusive thrombosis of IRA and there were no differ-
ences between tertiles (P = 0.45). Left main was affected approxi-
mately in 15% in all tertiles (P = 0.99) (Table 1).
Multivessel PCI was performed with similar frequency in all bSS
tertiles (28%) and the use of drug-eluting stents (33%) did not differ
between the groups. Complete revascularization (rSS 0) was achieved
in 28% of the patients. rSS was lower in the first and the second ter-
tiles in comparison with the third tertile (both P < 0.01). More than
half of the patients (n = 36, 59%) had shock before PCI (Table 1) but
there was no difference in either SS whether the patient had shock
before or after the procedure (Supporting Information Table 1). At dis-
charge, 94% of the patients were on dual antiplatelet therapy
(Table 1).
3.3 | Mortality
All-cause 90-day mortality was 43%. Mortality rate was lower in the
first tertile (19%), in comparison with the second (50%) and the third
tertiles (60%) (Figure 2A). In univariate analysis, bSS predicted 90-day
mortality (HR 1.04, 95% CI 1.01–1.08) and the association was inde-
pendent after adjustment for control variables (HR 1.06, 95% CI
1.01–1.10). bSS predicted mortality also after adjustment with the
IABP-SHOCK II (HR 1.05, 95% CI 1.01–1.09) and GRACE (HR 1.04,
95% CI 1.00–1.08) risk scores but not when adjusted for the Card-
Shock risk score (HR 1.02, 95% CI 0.98–1.06) (Table 2A).
There were no statistically significant differences in mortality
when using different rSS cutoff points (0, 8, and 12) (Figure 2B,D). In
univariate analysis, rSS as a continuous variable correlated with
90-day mortality (HR 1.04, 95% CI 1.00–1.07), but not independently
in any of the multivariable models (Table 2A). rSS as a categorical vari-
able did not associate with mortality in univariate or multivariable
analysis (Table 3A). There was no interaction between the timing of
CS (before or after coronary angiography) and rSS. Figure 3 depicts
the ROC-curves and AUCs for the bSS and rSS in comparison with the
three risk scores.
4 | DISCUSSION
To the best of our knowledge, this is the first study that evaluates the
prognostic value of bSS and rSS in patients with STEMI-related
CS. We found distinctive improvement from bSS to rSS implying suc-
cessful revascularization. bSS seems to associate with short-term mor-
tality, but the additive value over pre-existing clinical risk scores is
limited. The prognostic effect of rSS could not be shown, but post-PCI
TIMI flow 3 of IRA predicted better survival.
The median bSS in this study was lower than in the original SYN-
TAX study,22 but higher than in previous studies concerning
STEMI.2,5,6,12 The median bSS was higher than described in another
CS population,23 yet the definition of CS in our study was stricter.
Most of the patients in this study had multivessel disease and one
fourth had CTO, indicating that the patients with STEMI-related CS
have pre-existing complex coronary artery lesions. Regarding the risk
of CS in STEMI patients, CS has been more prevalent in the patients
with high SS5,6 and SS has been identified as an independent predictor
of CS in ACS patients.23 The results are in line with our finding of high
bSS in STEMI-related CS.
The prognostic value of bSS in STEMI-related CS was evaluated
for the first time. bSS retained prognostic value in CS but its clinical
relevance was limited, especially when added to recently developed
risk scores for CS. The result differs to some extent from observations
in non-shock STEMI patients in which bSS was credited with a robust
predictive value.2,4–6,10 However, in these STEMI populations, the
FIGURE 1 Patient flowchart—STEMI patients treated with primary
PCI or rescue PCI were included in this substudy. Exclusion criteria
were previous CABG, emergency CABG after angiography, or
mechanical complication of STEMI as an etiology of CS
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prevalence of CS was very low, which could explain the difference in
outcomes. In the present study, bSS had some additive predictive
value over the GRACE and IABP-SHOCK II risk scores. Previously, in a
non-CS STEMI population, bSS was shown to be useful in risk
stratification over GRACE risk score.24 Nevertheless, we believe, that
in the acute clinical context of CS, using clinical risk scores for risk
stratification is more feasible and accurate than assessing the exact
burden of coronary artery disease with bSS. However, the sample size
TABLE 1 Baseline characteristics, SYNTAX scores, clinical data, and mortality in bSS1 tertiles
First tertile bSS1 ≤ 18 Second tertile bSS1 19–27 Third tertile bSS > 27
P-valuen = 21 n = 20 n = 20
Age, years (SD) 62 (12) 68 (13) 70 (12) 0.92
Male gender, n (%) 20 (95%) 14 (70%) 18 (90%) 0.06
Resuscitation, n (%) 9 (43%) 7 (35%) 3 (15%) 0.12
SYNTAX scores
bSS2, pts (IQR) 7 (4–11) 13 (12–16) 32 (22–36) <0.01
rSS, pts (IQR) 0 (0–5) 6 (1.0–10) 20 (10–28) <0.01
Medical history
Coronary artery disease, n (%) 2 (10%) 4 (20%) 7 (35%) 0.13
Previous PCI, n (%) 0 (0%) 3 (15%) 6 (30%) <0.01
Diabetes, n (%) 5 (24%) 2 (10%) 8 (40%) 0.08
Hypertension, n (%) 11 (52%) 11 (55%) 13 (65%) 0.69
Hypercholesterolemia, n (%) 10 (48%) 11 (55%) 9 (45%) 0.81
Smoking, n (%) 13 (62%) 14 (70%) 8 (42%) 0.08
Clinical parameters
LVEF, % (SD) 37 (15) 34 (14) 29 (9) 0.17
SBP, mmHg (SD) 77 (23) 77 (11) 76 (12) 0.98
Serum lactate, mmol/l (IQR) 2.2 (1.2–3.2) 2.3 (1.7–6.3) 2.8 (2.1–4.4) 0.31
Creatinine, μmol/l (IQR) 89 (72–110) 97 (74–116) 112 (85–136) 0.20
eGFR, ml/min (IQR) 88 (65–104) 78 (42–98) 67 (41–87) 0.15
Hs-TnT, ng/l (IQR) 2,427 (849–6,810) 7,236 (3,677–11,943) 2,889 (1,828–8,965) 0.04
NT-proBNP, ng/l (IQR) 198 (133–942) 1,471 (253–3,977) 3,914 (481–16,551) <0.01
Angiographic data
Acute occlusive thrombosis, n (%) 12 (57%) 15 (75%) 12 (60%) 0.45
Chronic total occlusion, n (%) 1 (4.8%) 1 (5.0%) 15 (75%) <0.01
One-vessel disease, n (%) 14 (67%) 8 (42%) 0 (0%) <0.01
Three-vessel disease, n (%) 1 (4.8%) 2 (11%) 11 (55%) <0.01
Multivessel disease, n (%) 7 (33%) 11 (55%) 20 (100%) <0.01
Left main disease, n (%) 3 (14%) 3 (16%) 3 (15%) 0.99
CS before angiography, n (%) 12 (57%) 13 (65%) 11 (55%) 0.79
Time from shock to angiography, min (IQR) 68 (23–112) 40 (15–86) 75 (15–90) 0.57
Time from angiography to shock, min (IQR) 180 (60–300) 20 (15–75) 98 (45–175) 0.47
Second PCI, n (%) 0 (0%) 1 (5.0%) 1 (5%) 0.41
Treatment
Multivessel PCI, n (%) 4 (19%) 6 (30%) 7 (35%) 0.50
Drug-eluting stent, n (%) 8 (38%) 6 (30%) 6 (30%) 0.82
Complete revascularization (rSS 0), n (%) 12 (57%) 5(25%) 0 (0%) <0.01
Post-PCI TIMI 3, n (%) 14 (67%) 12 (60%) 14 (74%) 0.66
IABP, n (%) 10 (48%) 14 (70%) 13 (65%) 0.31
Medication at dischargea
Aspirina, n (%) 16 (94%) 11 (100%) 8 (100%) 0.47
Clopidogrel/prasugela, n (%) 15 (88%) 11 (100%) 7 (88%) 0.22
Endpoints
90-Day mortality, n (%) 4 (19%) 10 (50%) 12 (60%) 0.02
Abbreviations: bSS, baseline SYNTAX Score; CS, cardiogenic shock; eGFR, estimated glomerular infiltration; hs-TnT, high-sensitivity troponin T; IABP,
intra-aortic balloon pump; LVEF, left ventricular ejection fraction; MACCE, major adverse cardiac and cerebrovascular events; NT-proBNP, N-terminal
pro-b-type natriuretic peptide; PCI, percutaneous coronary intervention; rSS, residual SYNTAX Score; SBP, systolic blood pressure. Data are presented as
numbers (%), means (SD) and medians (IQR).
a Percentages calculated in patients who were discharged (n = 36).
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FIGURE 2 Ninety-day survival analysis—A, Kaplan–Meier’s survival curves in bSS1 tertiles; B–D, and in different rSS cutoff points [Color figure
can be viewed at wileyonlinelibrary.com]
TABLE 2 The Cox survival models with bSS and rSS as continuous variable for 90-day all-cause mortality
(A) HR 95% CI P-value HR 95% CI P-value
Univariable bSSb 1.04 1.01–1.08 0.02 rSSb 1.04 1.00–1.08 0.04
Multivariable
Control variablesa
bSSb 1.06 1.01–1.10 0.03 rSSb 1.03 0.99–1.08 0.14
LVEFc 1.80 1.22–2.65 <0.01 LVEFc 1.87 1.31–2.69 <0.01
Lactated 1.23 1.08–1.39 <0.01 Lactated 1.21 1.08–1.36 <0.01
Post-PCI TIMI 3 0.26 0.10–0.65 <0.01 Post-PCI TIMI 3 0.28 0.11–0.67 <0.01
Clinical risk scores
CardShockb 1.79 1.36–2.34 <0.01 CardShockb 1.81 1.38–2.37 <0.01
bSSb 1.02 0.98–1.06 0.29 rSSb 1.02 0.98–1.06 0.44
IAPB-SHOCK IIb 2.00 1.52–2.62 <0.01 IAPB-SHOCK IIb 1.86 1.42–2.42 <0.01
bSSb 1.05 1.01–1.09 <0.01 rSSb 1.03 0.99–1.07 0.08
GRACEb 1.02 1.00–1.03 0.01 GRACE b 1.02 1.00–1.03 0.01
bSSb 1.04 1.00–1.08 0.04 rSSb 1.03 0.99–1.07 0.11
a See Section 2 for variables assessed.
b Per one point increase.
c Per 10% decrease.
d Per 1 mmol/l increase.
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in this study is quite small, meaning that the mortality analyses do
have to be assessed with caution.
Regarding the analysis of rSS, some of the patients were diag-
nosed with CS only after coronary angiography, when optimally, all
patients should have presented with CS before revascularization.
However, this study reflects real life practice, since CS most often
develops during hospitalization,25 and in the current era of immediate
revascularization in STEMI, it is evident that some patients develop
CS only after the procedure. In addition, most study patients who
developed CS after revascularization, did it during the first hours after
angiography, suggesting that the pathophysiologic changes of CS had
probably started even before coronary angiography, and some clinical
signs of CS may already have been present. Therefore, we believe our
results can be useful in the clinical practice.
The distinctive improvement from bSS to rSS implies successful
revascularization. However, the rate of complete revascularization
(rSS 0) was lower than in prior studies13,20,21,26 and it was reached
most often in patients with the lowest bSS. As complete revasculariza-
tion is not always achievable in acute setting, previous studies have
examined the concept of reasonable incomplete revascularization in
ACS, but not in CS. Previously, the cutoff has been most often set at
rSS 8,14,20,21,27 or 12 points.9,12 In contrast to the earlier studies in
non-CS populations, we found no prognostic effect whether we used
the rSS cutoff of 8 or 12 points.
We could not demonstrate any predictive value of rSS in STEMI-
related CS. In previous studies, rSS independently predicted mortality
in STEMI.12,14,27 Recent CULPRIT-SHOCK trial showed worse survival
in CS in patients treated with multivessel PCI in comparison with
revascularization of culprit artery only,8 and the earlier studies have
shown similar results28 or they have found no survival benefit.29 In
our study, rSS had only modest association with mortality in univariate
analysis, but the prognostic value was outweighed by the clinical vari-
ables and the risk scores in adjusted analysis. The difference in the
predictive power of rSS probably relates to the difference between
TABLE 3 The Cox survival models with rSS as categorical variable
with different cutoffs for 90-day all-cause mortality
HR 95% CI P-value
(A)
Univariable rSS > 0 2.34 0.81–6.80 0.09
rSS ≥ 8 1.55 0.72–3.35 0.27
rSS ≥ 12 2.05 0.93–4.52 0.08
Multivariable
Control variablesa LVEFb <0.01e
Lactatec <0.01e
Post-PCI TIMI 3 <0.01e
and either (1) rSS > 0 2.46 0.83–7.29 0.11
(2) rSS ≥ 8 1.27 0.55–2.94 0.58
(3) rSS ≥ 12 1.54 0.65–3.66 0.33
Clinical risk scores
CardShockd <0.01e
and either (1) rSS > 0 2.41 0.80–7.26 0.12
(2) rSS ≥ 8 1.05 0.48–2.31 0.91
(3) rSS ≥ 12 1.26 0.55–2.88 0.58
IABP-SHOCK IId <0.01e
and either (1) rSS > 0 2.05 0.70–6.00 0.19
(2) rSS ≥ 8 1.36 0.62–2.99 0.45
(3) rSS ≥ 12 1.53 0.67–3.49 0.31
GRACEd 0.01e
and either (1) rSS > 0 1.83 0.62–5.43 0.28
(2) rSS ≥ 8 1.44 0.67–3.11 0.36
(3) rSS ≥ 12 1.71 0.77–3.80 0.19
a See Section 2 for variables assessed.
b Per 10% decrease.
c Per one mmol/l increase.
d Per one point increase.
e P-values calculated and valid for all categorical rSS multivariable models.
FIGURE 3 The prognostic ability of SYNTAX scores—ROC curves of bSS, rSS, and clinical risk scores [Color figure can be viewed at
wileyonlinelibrary.com]
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the severity of clinical condition, i.e., CS and any ACS. The patients in
our study were seriously ill: one third of the patients had been resusci-
tated and over half had CS before PCI. In such circumstances, revascu-
larization is challenging, and treatment targets must include
hemodynamic stability, adequate organ perfusion and limiting multi-
organ failure. Regarding the timing of CS and the completeness of
revascularization, we found that rSS was equal in patients who devel-
oped CS before or after angiography. This finding could suggest that
less complete revascularization was not the cause of CS in the patients
who developed CS after the procedure. However, considering the small
sample size of the study, straightforward conclusions are difficult to
make regarding the relationship between the failure of revascularization
and the cause of the CS. Nevertheless, in line with previous studies,
successful revascularization of the IRA, defined as achieving post-PCI
TIMI flow 3, was associated with lower mortality.16 This may suggest
that restoring the blood flow to the IRA is more important than target-
ing complete revascularization and low rSS.
5 | LIMITATIONS
Several limitations of our study need to be considered. First, the
cohort consists of a limited number of patients, and despite high mor-
tality rates, the number of events in mortality analyses is small. Never-
theless, this is to our knowledge the first, and thus the largest analysis
of SS in a cohort of CS patients. Second, interpretation of the angio-
grams was not centralized, but the SS was analyzed in each hospital
by one local experienced cardiologist. However, both were well
trained to calculate the SS. Third, the CardShock risk score was devel-
oped from the original CardShock cohort including also the patients in
the current study, which could affect the analysis of the prognostic
value of bSS and rSS over the CardShock risk score. However, the
added value of SS was limited also when comparing to two other risk
scores.
6 | CONCLUSION
In STEMI-related CS, the additive value of bSS and rSS over clinical
assessment and risk scores is limited. Our results support that in
STEMI-related CS, restoring the blood flow to the IRA is essential, and
more important than opting for the complete revascularization
with PCI.
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